Valproate therapy and nonalcoholic fatty liver disease
Authors:
- 25 March 2004
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 55 (5) , 729-732
Abstract
Nonalcoholic fatty liver disease was defined recently as another symptom of insulin resistance. Continuous therapy with valproate can result in increased body weight and insulin resistance, but no data are yet available on a possible relationship between valproate and nonalcoholic fatty liver disease. We here demonstrate in abdominal ultrasound investigations that characteristics of fatty liver disease were present in 61% of valproate‐treated patients as compared with 23% receiving carbamazepine therapy. Ann Neurol 2004Keywords
This publication has 18 references indexed in Scilit:
- Diagnosis of fatty liver diseaseEuropean Journal of Gastroenterology & Hepatology, 2003
- Metabolic SyndromeCirculation, 2002
- Polycystic ovaries, obesity and insulin resistance in women with epilepsyJournal of Neurology, 2002
- Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2002
- Pharmacological and Therapeutic Properties of ValproateCNS Drugs, 2002
- Valproate, lamotrigine, and insulin‐mediated risks in women with epilepsyAnnals of Neurology, 1998
- Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitisProceedings of the National Academy of Sciences, 1997
- Obesity and endocrine disorders in women taking valproate for epilepsyAnnals of Neurology, 1996
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985
- Hepatotoxicity to sodium valproate: a review.Gut, 1984